India, Sept. 29 -- On Tuesday, Veracyte (VCYT) announced new findings from a retrospective analysis of the Phase 3 NRG/RTOG 0815 trial showing that its Decipher Prostate Genomic Classifier can identify intermediate-risk prostate cancer patients more likely to benefit from adding short-term hormone therapy to radiation.
The findings will be presented on September 29 at the 2026 ASTRO Annual Meeting in San Francisco as Abstract 312, during an oral session from 3:55-4:05 p.m. ET.
Prostate cancer is the most commonly diagnosed cancer among men in the U.S., with treatment decisions often based on clinical factors such as tumor grade, PSA levels and disease stage.
Androgen deprivation therapy (ADT), which lowers male hormones that can fuel pro...